Bellevue Group’s Genmab GMAB Stock Holding History

Bellevue Group’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,009	Closed	-$92.7K	–	173
2025 Q4	$92.7K	Hold	3,009	–	–	﹤0.01%	166
2025 Q3	$92.3K	Buy	+3,009	New	+$73.3K	﹤0.01%	143

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Bellevue Group's GMAB Position: Q1 2026 in Review

Bellevue Group sold out of Genmab (GMAB) in Q1 2026, closing a stake of 3,009 shares — an estimated $92.7K sold.

Bellevue Group first reported a position in GMAB in Q3 2025 and held it in 2 quarters. The position peaked at $92.7K in Q4 2025. 274 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Bellevue Group reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
Bellevue Group sold 3,009 Genmab shares in Q1 2026, an estimated $92.7K.
Bellevue Group first reported a position in Genmab in Q3 2025 and held it in 2 quarters.
Bellevue Group's Genmab position peaked at $92.7K in Q4 2025.
274 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.